Introduction
============

Obstructive sleep apnea (OSA), which presents in \~9% of females and 24% of males, is characterized by repetitive upper airway obstruction in breathing during sleep and is usually associated with hypertension, arrhythmia, heart failure, insulin resistance, and cerebrovascular accident.[@b1-ppa-10-871],[@b2-ppa-10-871] It has also been shown that the prevalence of OSA in patients with coronary artery disease (CAD) was two times more than that in those without CAD, with increased risk of mortality and myocardial infarction (MI), which was believed to be caused by hypoxia, enhanced inflammation, oxidative stress, and endothelial dysfunction.[@b1-ppa-10-871],[@b3-ppa-10-871],[@b4-ppa-10-871] So far, percutaneous coronary intervention (PCI) has been the crucial treatment for symptomatic CAD; however, there is a paucity of evidence regarding the association between OSA and patients undergoing PCI. In 89 consecutive patients with acute coronary syndrome (ACS) treated with PCI, the incidence of cardiac death, reinfarction, and target vessel revascularization (TVR) at 8-month follow-up was 23.5% in the OSA group, which was significantly higher than 5.3% in patients without OSA.[@b5-ppa-10-871] However, the advanced devices, especially the new generation of drug-eluting stent (DES), were not used in the small-scale study with short follow-up. Therefore, this prospective study is designed to address the long-term clinical impact of OSA in patients undergoing PCI.

Patients and methods
====================

Study population
----------------

From October 2012 to April 2014, a total of 1,130 consecutive real-world patients who were treated with DES implantation at our center were considered as candidates for this study. Finally, 340 patients were included in the study according to the inclusion and exclusion criteria. Inclusion criteria were as follows: age \>18 years and successful PCI in at least one major epicardial coronary artery. Exclusion criteria are shown in [Figure 1](#f1-ppa-10-871){ref-type="fig"}. Of note, patients with OSA receiving any relevant treatments were excluded. The protocol was approved by the Institutional Ethics Committee of Nanjing First Hospital, and written informed consent was obtained from all patients.

Percutaneous coronary intervention
----------------------------------

All interventional procedures were performed in accordance with the current guidelines. Use of the type of DES, glycoprotein IIb/IIIa inhibitors, intravascular ultrasound, fractional flow reserve, and optical coherence tomography was at the operator's discretion. A loading dose of clopidogrel (300 mg) or ticagrelor (180 mg) was administered before the index procedure. Total creatine kinase, creatine kinase-myocardial band, and troponin were dynamically measured until 72 hours postprocedure. After the intervention, all patients received 100 mg/d aspirin indefinitely and clopidogrel (75 mg/d) or ticagrelor (90 mg/d bid) for at least 12 months.

Sleep study
-----------

All overnight sleep studies for eligible patients were conducted using the Embletta Gold standardized level-3 portable diagnostic system (Natus Medical Inc., Ontario, Canada) 7--10 days after the index PCI procedure,[@b6-ppa-10-871],[@b7-ppa-10-871] which included nasal airflow, thoracoabdominal movements, arterial oxygen saturation, snoring episodes, limb movement, electrocardiogram, and body position. All sleep studies were reviewed by an independent sleep specialist according to the guidelines,[@b8-ppa-10-871] and the poor quality of sleep tracings were excluded from the final analysis of the sleep data. Two independent sleep technologists with registered polysomnographic technologist credentials manually analyzed all studies. The respiratory events of sleep study were performed in accordance with the American Association of Sleep Medicine Guidelines.[@b8-ppa-10-871] The primary measurement of the sleep study was the apnea--hypopnea index (AHI), which "was used to stratify patients" into the OSA (AHI ≥15) and non-OSA groups (AHI \<15).[@b9-ppa-10-871]

Study end points and definitions
--------------------------------

The primary end point was the rate of major adverse cardiac events (MACEs) at 2 years, including cardiac death, MI, and/or TVR. The safety end point was the occurrence of stent thrombosis (ST). All deaths were considered cardiac in origin unless a noncardiac cause was confirmed clinically or at autopsy. MI was diagnosed in accordance with the Society for Cardiovascular Angiography and Interventions definition.[@b10-ppa-10-871] Target lesion revascularization, TVR, and ST were defined according to the Academic Research Consortium definition.[@b11-ppa-10-871]

Follow-up
---------

Clinical follow-up was performed either by telephone or through a clinical office visit at 1 month, 6 months, and 12 months, and every year thereafter. Repeat coronary angiography was scheduled at 12 months after the indexed procedure unless clinical reasons indicated earlier. An independent committee that was blinded to the study assessed all clinical events.

Quantitative coronary angiography
---------------------------------

Quantitative coronary angiographic analysis (QCA) at baseline, post-stenting, and at follow-up was performed offline using edge detection techniques (CAAS II, Version 5.0; Pie Medical, Maastricht, the Netherlands) by an independent core laboratory (China Cardiovascular Research Foundation, Beijing, People's Republic of China). QCA variables included reference vessel diameter, minimal lumen diameter, acute gain, late lumen loss, and net gain, which were defined in our previous study.[@b12-ppa-10-871]

Statistical analysis
--------------------

The distribution of continuous variables was assessed by the Kolmogorov--Smirnov test. Categorical variables were expressed as frequencies or percentages and compared using chi-square statistics or Fisher's exact test. Continuous variables were summarized as mean ± SD or median and compared using Student's *t*-test (for normal data) and Mann--Whitney *U*-test (for non-normally distributed variables). Survival curves were generated by the Kaplan--Meier method and compared using the log-rank test. Hazard ratios (HR) are presented along their 95% confidence interval (CI). Univariable and multivariable Cox proportional hazard models were applied to identify potential factors that correlated with MACEs. The variables showing statistical significance or a trend (*P*\<0.1) in univariable Cox model were subjected to multivariable analysis with a forced-entry method. A *P*-value \<0.05 was considered statistically significant, except for *P*-value \<0.01 in univariable analysis to minimize the probability of type I error. All analyses were performed using the statistical program SPSS 16.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Baseline clinical and sleep characteristics
-------------------------------------------

A total of 340 patients (average age: 64.69±10.38 years) with DES implantation were finally enrolled and assigned to the OSA (n=152, 44.7%) and non-OSA (n=188, 55.3%) groups stratified by the AHI. Baseline clinical and sleep characteristics are shown in [Table 1](#t1-ppa-10-871){ref-type="table"}. None of the 340 study patients had received treatments for OSA. Ten percent of the individuals were admitted with stable angina and the remaining with ACS. Patients in the OSA group were more likely to be males (78.9%) and had greater body mass index (BMI; 25.4±2.9 kg/mm^2^) and larger left ventricular end diastolic diameter (LVDd; 50.6±6.8 mm), when compared to the non-OSA group (68.6%, *P*=0.032; 24.5±3.1 kg/mm^2^, *P*=0.007; 48.2±4.6 mm, *P*=0.003). The median AHI of 340 enrolled patients was 13.8, and the median time for SpO~2~ level \<90% was 16.3 minutes in the OSA group, which was significantly higher than the \>5.1 minutes in the non-OSA group (*P*\<0.001).

Lesions and procedural characteristics
--------------------------------------

[Table 2](#t2-ppa-10-871){ref-type="table"} shows that patients in the OSA group had more three-vessel disease (34.9%), increased number of total implanted stents (3.3±2.0), and larger total stent length (83.8±53.1 mm) when compared to the non-OSA group (23.4%, *P*=0.020; 2.8±1.9, *P*=0.007; 68.7±48.4, *P*=0.010). As a result, the OSA group had higher procedural time (64.0±49.7 minutes vs 52.8±39.6 minutes, *P*=0.026).

OSA and cardiovascular events
-----------------------------

After a median follow-up of 2 years, there were 38 (25.0%) composite MACEs in the OSA group and 30 (16.0%) in the non-OSA group (*P*=0.038), which were mainly driven by the more periprocedural MI (19.2%) in the OSA group compared to the non-OSA group (11.2%, *P*=0.038; [Table 3](#t3-ppa-10-871){ref-type="table"}, [Figure 2](#f2-ppa-10-871){ref-type="fig"}). By Cox regression multivariable analysis, the independent predictor of MACEs was OSA (HR: 1.962, 95% CI: 1.036--3.717, *P*=0.039; [Table 4](#t4-ppa-10-871){ref-type="table"}). There were no significant differences in QCA between the OSA and non-OSA groups ([Table 5](#t5-ppa-10-871){ref-type="table"}).

Subgroup analysis
-----------------

[Figure 3](#f3-ppa-10-871){ref-type="fig"} shows the results of subgroup analysis for the associations between OSA and risk of MACEs in patients with DES implantation at 2 years. The incidence of composite MACEs in the OSA group was more remarkable among male patients aged ≤75 years, with BMI \>25 kg/m^2^, hyperlipidemia, and ACS.

Discussion
==========

The major finding of the current study was that the high prevalence of moderate-to-severe OSA was found in patients with DES implantation, and OSA was associated with significantly increased 2-year composite MACE rate, mainly due to the increment of periprocedural MI rate.

In the current study, we found that 44.7% of patients with CAD undergoing PCI had moderate-to-severe OSA, which was similar to 48.3% and 57% in the current literature.[@b5-ppa-10-871],[@b13-ppa-10-871] With chronic intermittent hypoxemia, reoxygenation, and hypercapnia in patients with OSA, there is increased sympathetic activation, induction of oxidative stress, vasoconstriction, and provocation of inflammation leading to endothelial dysfunction and atherosclerosis.[@b1-ppa-10-871],[@b14-ppa-10-871],[@b15-ppa-10-871] Therefore, it is not surprising that the high prevalence of OSA was found in these patients with CAD undergoing PCI. In addition, the current study showed that patients with OSA were more likely to be males and had a significantly greater BMI, which was consistent with published data in the Randomized Intervention With Continuous Positive Airway Pressure in Coronary Artery Disease and Sleep Apnea trial,[@b16-ppa-10-871] suggesting that age, male, and BMI were predictors of OSA. Moreover, compared to patients without OSA, patients with OSA were more likely to undergo multivessel PCI and had an increased number of DESs implanted during PCI, which might be explained by chronic hypoxia, enhanced inflammation, oxidative stress, and endothelial dysfunction.[@b1-ppa-10-871],[@b3-ppa-10-871]

The association between OSA and adverse cardiac events has been explored in general population in several studies.[@b3-ppa-10-871],[@b4-ppa-10-871],[@b17-ppa-10-871] The Sleep Heart Health Study enrolling 1,927 men and 2,495 women free of CAD showed that OSA was a significant predictor of incident CAD, MI, revascularization procedure, or cardiovascular death after a median of 8.7-year follow-up.[@b4-ppa-10-871] In another long-term study including 1,436 patients, OSA increased the risk of coronary events or cardiovascular death, and OSA was an independent risk factor for cardiovascular events, including MI.[@b3-ppa-10-871] Similar negative effects of OSA could be found in patients with ACS.[@b11-ppa-10-871],[@b18-ppa-10-871],[@b19-ppa-10-871] In 168 consecutive patients with unstable angina or non-ST elevation acute MI, OSA had higher risk of cardiovascular complications during the acute phase of ACS.[@b11-ppa-10-871] Overall, the current data indicated that OSA has been associated with increased risk of adverse cardiac events in general population or patients with ACS.

Whether OSA adversely affected the prognosis of patients with stent placement for CAD has not been established, and there is a deficiency of evidence regarding the association between OSA and patients undergoing PCI. In 105 patients admitted with ST-segment elevation MI undergoing stent placement, severe OSA carried a negative prognostic impact for these patients after 18-month follow-up.[@b20-ppa-10-871] Another study which enrolled 89 consecutive patients with ACS treated with PCI showed that the incidence of cardiac death, reinfarction, and TVR at 8-month follow-up was 23.5% in the OSA group, significantly higher than 5.3% in patients without OSA.[@b5-ppa-10-871] However, the new generation of DES was not used in this small-scale study with short follow-up. Our data confirm this previous evidence and add some novel findings. First, to the best of our knowledge, this is the first study to demonstrate increased periprocedural MI rate of OSA after DES implantation in patients with CAD. Second, a great many angiographic and procedural variables, indicating anatomic severity for coronary disease and the potentially important confounding factors, were included and adjusted in this study. Third, subgroup analysis was conducted to identify a subset of patients undergoing PCI for whom an unfavorable effect of OSA was remarkable. Finally, the differences in techniques, lesion complexity, and DES types used may be impact factors attributed to the discrepancy in several results. However, results from a previous study[@b5-ppa-10-871] and ours demonstrated a negative effect of OSA on composite MACE rate in patients undergoing PCI for CAD.

Study limitations
-----------------

The current study has several limitations. First, none of the 340 study patients had received treatments for OSA, and it was not possible to evaluate the effects of continuous positive airway pressure treatment on cardiovascular outcome. Second, there were 42 sleep studies that were not successful due to premature device removal by the patients or technical errors, and it might not be possible to conduct a repeat sleep study in consideration of the short hospitalization period in patients after PCI. Third, patients were not tested for sleep data again in the follow-up. Thus, there was lack of information regarding post-discharge sleep data and the timing of cardiac events during the follow-up.

Conclusion
==========

The current study showed a high prevalence of moderate-to-severe OSA in patients with DES implantation for CAD, and OSA was associated with significantly increased 2-year composite MACE rate, mainly due to the increment of periprocedural MI rate.
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![Flowchart of study design.\
**Abbreviations:** CPAP, continuous positive airway pressure; DES, drug-eluting stent; IABP, intra-aortic balloon pump; OSA, obstructive sleep apnea; SBP, systolic blood pressure.](ppa-10-871Fig1){#f1-ppa-10-871}

![MACE-free survival rate at 2 years.\
**Note:** Freedom from MACEs between the OSA group (red line) and non-OSA group (blue line) at 2-year follow-up.\
**Abbreviations:** MACEs, major adverse cardiac events; OSA, obstructive sleep apnea.](ppa-10-871Fig2){#f2-ppa-10-871}

![Forest plots of 2-year MACE rate in the prespecified subgroups.\
**Note:** Data in the Events columns presented as number of events/total number of patients.\
**Abbreviations:** ACS, acute coronary syndrome; BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; MACEs, major adverse cardiac events; OR, odds ratio; OSA, obstructive sleep apnea.](ppa-10-871Fig3){#f3-ppa-10-871}

###### 

Baseline clinical and sleep characteristics of the OSA and non-OSA groups

  Characteristics               OSA (n=152)         Non-OSA (n=188)     *P*-value
  ----------------------------- ------------------- ------------------- -----------
  Age, years                    65.6±10.3           64.0±10.4           0.170
  Males, n (%)                  120 (78.9)          129 (68.6)          0.032
  BMI, kg/m^2^                  25.4±2.9            24.5±3.1            0.007
  Hypertension, n (%)           113 (74.3)          132 (70.2)          0.399
  Hyperlipidemia, n (%)         107 (70.9)          124 (66.0)          0.336
  Diabetes, n (%)               50 (32.9)           45 (23.9)           0.067
  Stroke, n (%)                 15 (9.9)            25 (13.3)           0.329
  Smoking status, n (%)                                                 0.083
   Current smoker               49 (32.2)           70 (37.2)           
   Former smoker                18 (11.8)           10 (5.3)            
  eGFR, mL/min/1.73 m^2^        105.7±28.8          126.0±30.2          0.358
  Previous MI, n (%)            23 (15.1)           18 (9.6)            0.118
  Stable angina, n (%)          17 (11.2)           17 (9.0)            0.513
  Unstable angina, n (%)        105 (69.1)          130 (69.1)          0.989
  STEMI, n (%)                  10 (6.6)            20 (10.6)           0.189
  NSTEMI, n (%)                 11 (7.2)            10 (5.3)            0.465
  CHF, n (%)                    24 (15.8)           21 (11.2)           0.211
  LVEF, %                       59.2±10.6           61.5±8.2            0.067
  LVDd, mm                      50.6±6.8            48.2±4.6            0.003
  Previous PCI, n (%)           33 (21.7)           32 (17.0)           0.274
  Previous CABG, n (%)          2 (1.3)             2 (1.1)             0.830
  PAD, n (%)                    4 (2.7)             2 (1.2)             0.319
  Sleep study characteristics                                           
   AHI                          30.9 (21.8, 43.5)   8.4 (3.9, 11.9)     \<0.001
   Average SpO~2~, %            93.3 (92.1, 94.3)   93.9 (92.8, 94.8)   0.001
   Lowest SpO~2~, %             82.0 (79.0, 85.0)   87.0 (82.0, 88.0)   \<0.001
   Time SpO~2~ \<90%, minutes   16.3 (5.7, 47.2)    5.1 (0.8, 26.9)     \<0.001
   Time SpO~2~ \<80%, minutes   0.4 (0.1, 1.4)      0.2 (0.0, 0.4)      0.041

**Note:** Continuous variables were summarized as mean ± standard deviation for normal data or median (quartile) for non-normally distributed variables.

**Abbreviations:** AHI, apnea--hypopnea index; BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVDd, left ventricular end diastolic diameter; MI, myocardial infarction; NSTEMI, non-STEMI; OSA, obstructive sleep apnea; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; ST, stent thrombosis; STEMI, ST-segment elevation MI.

###### 

Angiographic and procedural characteristics of the OSA and non-OSA groups

  Characteristics                     OSA (n=152)   Non-OSA (n=188)   *P*-value
  ----------------------------------- ------------- ----------------- -----------
  **Angiographic characteristics**                                    
  Number of diseased vessels                                          0.017
   One-vessel disease                 47 (30.9)     84 (44.7)         0.010
   Two-vessel disease                 52 (34.2)     60 (31.9)         0.654
   Three-vessel disease               53 (34.9)     44 (23.4)         0.020
  CTO lesion                                                          0.507
   LAD                                11 (7.2)      7 (3.7)           
   LCX                                5 (3.3)       6 (3.2)           
   RCA                                12 (7.9)      10 (5.3)          
   \>1 CTO                            1 (0.7)       2 (1.1)           
  Needing rotablation                 2 (1.3)       1 (0.5)           0.442
  Thrombus-containing lesions         7 (4.7)       7 (3.7)           0.673
  **Procedural characteristics**                                      
  Transradial, n (%)                  148 (97.4)    184 (97.9)        0.549
  IIb/IIIa inhibitor used, n (%)      18 (12.1)     18 (10.7)         0.688
  IVUS assessment, n (%)              31 (20.8)     29 (17.2)         0.407
  FFR assessment, n (%)               24 (16.1)     37 (21.9)         0.191
  OCT assessment, n (%)               9 (6.0)       8 (4.7)           0.605
  DES used, n (%)                     152 (100)     188 (100)         NS
  Total implanted stents              3.3±2.0       2.8±1.9           0.007
  Mean stent diameter, mm             3.0±0.4       3.0±0.4           0.279
  Total stent length, mm              83.8±53.1     68.7±48.4         0.010
  Complete revascularization, n (%)   96 (63.2)     132 (70.2)        0.169
  Final TIMI grade 3, n (%)           150 (98.7)    187 (99.5)        0.193
  Procedural time, minutes            64.0±49.7     52.8±39.6         0.026
  Contrast volume, mL                 211.0±108.1   190.2±89.3        0.053

**Notes:** Continuous variables were summarized as mean ± standard deviation for normal data or median (quartile) for non-normally distributed variables. Categorical variables were expressed as percentages.

**Abbreviations:** CTO, chronic total occlusion; DES, drug-eluting stent; FFR, fractional flow reserve; IVUS, intravascular ultrasound; LAD, left anterior descending artery; LCX, left circumflex artery; MI, myocardial infarction; NS, nonsignificant; OCT, optical coherence tomography; OSA, obstructive sleep apnea; RCA, right coronary artery; TIMI, thrombolysis in MI.

###### 

Clinical outcomes in the OSA and non-OSA groups

  Outcomes                 OSA (n=152)   Non-OSA (n=188)   *P*-value
  ------------------------ ------------- ----------------- -----------
  **In-hospital, n (%)**                                   
  Cardiac death            0             0                 NS
  Periprocedural MI        29 (19.2)     21 (11.2)         0.038
  Spontaneous MI           0             0                 NS
  TLR                      0             0                 NS
  CABG                     0             0                 NS
  TVR                      0             0                 NS
  MACEs                    0             0                 NS
  ST                       0             0                 NS
  **At 1 year, n (%)**                                     
  Cardiac death            1 (0.7)       1 (0.5)           0.880
  Periprocedural MI        29 (19.2)     21 (11.2)         0.038
  Spontaneous MI                                           
   STEMI                   0             0                 NS
   NSTEMI                  2 (1.3)       1 (0.5)           0.442
  TLR                      5 (3.3)       5 (2.7)           0.773
  CABG                     1 (0.7)       0                 0.265
  TVR                      7 (4.6)       5 (2.7)           0.334
  MACEs                    37 (24.3)     27 (14.4)         0.019
  ST                       2 (1.3)       2 (1.1)           0.830
  **At 2 years, n (%)**                                    
  Cardiac death            3 (2.0)       1 (0.5)           0.220
  Periprocedural MI        29 (19.2)     21 (11.2)         0.038
  Spontaneous MI                                           
   STEMI                   0             0                 NS
   NSTEMI                  2 (1.3)       1 (0.5)           0.442
  TLR                      6 (3.9)       8 (4.3)           0.887
  CABG                     1 (0.7)       0                 0.265
  TVR                      8 (5.3)       9 (4.8)           0.841
  MACEs                    38 (25.0)     30 (16.0)         0.038
  ST                       3 (2.0)       2 (1.1)           0.660

**Abbreviations:** CABG, coronary artery bypass grafting; MACEs, major adverse cardiac events; MI, myocardial infarction; NS, nonsignificant; NSTEMI, non-ST segment elevation MI; OSA, obstructive sleep apnea; ST, stent thrombosis; STEMI, ST segment elevation MI; TLR, target lesion revascularization; TVR, target vessel revascularization.

###### 

Univariate and multivariate analyses for MACEs

  Variables                Univariate analysis; HR (95% CI)   *P*-value   Multivariate analysis; HR (95% CI)   *P*-value
  ------------------------ ---------------------------------- ----------- ------------------------------------ -----------
  Age                      0.999 (0.976, 1.022)               0.916                                            
  Male                     1.235 (0.705, 2.163)               0.461                                            
  BMI                      1.051 (0.980, 1.126)               0.163                                            
  Hypertension             0.940 (0.558, 1.584)               0.817                                            
  Current smoker           1.244 (0.765, 2.022)               0.379                                            
  Diabetes mellitus        0.845 (0.488, 1.463)               0.548                                            
  Ejection fraction        0.976 (0.952, 1.002)               0.069       0.985 (0.955, 1.015)                 0.315
  hsCRP                    0.998 (0.971, 1.026)               0.875                                            
  OSA                      1.627 (1.007, 2.628)               0.047       1.962 (1.036, 3.717)                 0.039
  Total implanted stents   1.069 (0.953, 1.199)               0.253                                            
  Multivessel disease      1.453 (0.869, 2.432)               0.155                                            

**Note:** Multivariate analysis data is not shown for several variables because these variables did not enter the multivariate model for their nonsignificant results in the univariate analysis.

**Abbreviations:** BMI, body mass index; CI, confidence interval; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; MACEs, major adverse cardiac events; OSA, obstructive sleep apnea.

###### 

Quantitative coronary analysis of the OSA and non-OSA groups

  Variables                     OSA (231 lesions)   Non-OSA (277 lesions)   *P*-value
  ----------------------------- ------------------- ----------------------- -----------
  Lesion length, mm             35.22±19.18         31.82±19.45             0.048
  Preprocedure                                                              
   Reference diameter, mm       2.83±0.46           2.85±0.49               0.621
   Minimal lumen diameter, mm   1.03±0.56           1.05±0.61               0.647
   Diameter stenosis, %         64.21±18.87         63.46±20.29             0.669
  Postprocedure                                                             
   Reference diameter, mm       2.96±0.45           2.96±0.46               0.961
   Minimal lumen diameter, mm   2.59±0.46           2.56±0.51               0.453
   Diameter stenosis, %         12.71±6.21          13.74±9.69              0.165
   Acute gain, mm               1.56±0.56           1.51±0.61               0.283
  At follow-up                                                              
   Reference diameter, mm       2.95±0.43           2.97±0.46               0.700
   Minimal lumen diameter, mm   2.41±0.61           2.40±0.61               0.796
   Diameter stenosis, %         18.83±14.79         19.86±13.95             0.492
   Late loss, mm                0.19±0.40           0.21±0.33               0.604
   Net gain, mm                 1.37±0.66           1.33±0.67               0.523
   Restenosis, %                12 (6.6)            7 (3.5)                 0.165

**Notes:** Continuous variables were summarized as mean ± standard deviation for normal data or median (quartile) for non-normally distributed variables. Categorical variables were expressed as percentages.

**Abbreviation:** OSA, obstructive sleep apnea.
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